News

to-BBB has entered into a research collaboration with Genzyme to evaluate to-BBB’s proprietary G-Technology to safely enhance delivery of biologics for neurodegenerative diseases. G-Technology is designed to transport

InteRNA Technologies and the Dana-Farber Cancer Institute have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer. Under the collaboration with William Hahn, associate professor

Quintiles has entered into a clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas around the globe. Quintiles is expected to assume

GlaxoSmithKline (GSK) and Valeant Pharmaceuticals (Valeant) have provided updates on the New Drug Application for retigabine. GSK and Valeant had filed a New Drug Application with the FDA

Amylin Pharmaceuticals (Amylin) and Takeda Pharmaceutical (Takeda) have entered into a worldwide exclusive license, development and commercialisation agreement to co-develop and commercialise pharmaceutical products for the treatment of

Schering-Plough has reported that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a phase III study of adult subjects in

Abbott has acquired the remaining outstanding equity of Evalve that it did not already own for an upfront payment of $320m, plus a $90m payment if certain regulatory

Caliper Life sciences, has launched two new products that expand the LabChip GX product line: a GLP/GMP-compliant version of the operating software for the LabChip GX instrument that

Solasia Pharma (Solasia) has completed phase I clinical trial for SP-01 (extended release transdermal granisetron patch, brand name: Sancuso ) in Japanese volunteers. Sancuso is the first and